Molecular biomarkers and integrated pathological diagnosis in the reclassification of gliomas

  • Authors:
    • María Fernanda Ruiz
    • María Verónica Gennaro
    • Laura C. Bastone
    • Alicia R. Godoy
    • Mónica Torruella
    • Germán R. Perez
  • View Affiliations

  • Published online on: May 31, 2021     https://doi.org/10.3892/mco.2021.2312
  • Article Number: 150
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to evaluate the impact caused by the 2016 World Health Organization (WHO) diagnostic classification of gliomas in 139 patients studied in Argentina. Formalin‑fixed paraffin‑embedded tissues were used for histological and immunohistochemical analysis [glial fibrillary acidic protein, KI67, synaptophysin and isocitrate dehydrogenase (IDH)1‑R132H]. DNA from formalin‑fixed paraffin‑embedded tissues was used for molecular analysis: 1p/19q co‑deletion and mutation status of the IDH gene. These experiments were performed by direct Sanger sequencing and multiplex ligation‑dependent probe amplification. According to the new classification, diagnoses included oligodendroglioma IDH‑mutant and 1p/19q co‑deletion (4.20%), anaplastic oligodendroglioma IDH‑mutant and 1p/19q co‑deletion (2.52%), diffuse astrocytoma IDH‑mutant (6.72%), diffuse astrocytoma IDH‑wild type (1.68%), anaplastic astrocytoma IDH‑mutant (5.04%), anaplastic astrocytoma IDH‑wild type (8.40%), glioblastoma IDH‑mutant (5.88%) and glioblastoma IDH‑wild type (65.56%). Regarding tumor histology, 60% of oligodendrogliomas, 35% of astrocytoma and 100% of unclassified gliomas were re‑classified, while glioblastomas maintained their initial classification. Additionally, the present study evaluated the prognostic value of the histological grade for the 2007 and 2016 WHO classifications of gliomas. The histological subgroup associated with longer overall survival (OS) was grade II glioma (OS‑2007WHO, 35.6 months; and OS‑2016WHO, 47.7 months). Glioblastoma was the subgroup associated with a poor outcome (OS‑2007WHO, 10.4 months; and OS‑2016WHO, 11.1 months). The present study evaluated the OS of tumor grade subgroups with respect to their IDH status. For all subgroups, IDH‑mutant tumors were associated with an improved prognosis compared with IDH‑wild type tumors. The results suggested that the incorporation of molecular biomarkers in the new WHO classification improves tumor characterization and prognostic value of the subgroups.
View Figures
View References

Related Articles

Journal Cover

August-2021
Volume 15 Issue 2

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ruiz MF, Gennaro MV, Bastone LC, Godoy AR, Torruella M and Perez GR: Molecular biomarkers and integrated pathological diagnosis in the reclassification of gliomas. Mol Clin Oncol 15: 150, 2021
APA
Ruiz, M.F., Gennaro, M.V., Bastone, L.C., Godoy, A.R., Torruella, M., & Perez, G.R. (2021). Molecular biomarkers and integrated pathological diagnosis in the reclassification of gliomas. Molecular and Clinical Oncology, 15, 150. https://doi.org/10.3892/mco.2021.2312
MLA
Ruiz, M. F., Gennaro, M. V., Bastone, L. C., Godoy, A. R., Torruella, M., Perez, G. R."Molecular biomarkers and integrated pathological diagnosis in the reclassification of gliomas". Molecular and Clinical Oncology 15.2 (2021): 150.
Chicago
Ruiz, M. F., Gennaro, M. V., Bastone, L. C., Godoy, A. R., Torruella, M., Perez, G. R."Molecular biomarkers and integrated pathological diagnosis in the reclassification of gliomas". Molecular and Clinical Oncology 15, no. 2 (2021): 150. https://doi.org/10.3892/mco.2021.2312